Skip to main content
. 2021 Nov 5;42(1):31–39. doi: 10.1007/s00296-021-05039-3

Table 2.

Vaccination characteristics of patients included in the study

COVID-19 vaccinated n = 441
Vaccine
 Pfizer, n (%) 380 (86.2)
 Moderna, n (%) 14 (3.2)
 Astra-Zeneca, n (%) 44 (10.0)
 Johnson & Johnson, n (%) 3 (0.7)
Adverse effects, rates 148/441
 1st dose, n (%) 107 (24.3)
 2nd dose, n (%) 108 (24.5)
 Both doses, n (%) 67 (15.2)
Disease flare, rates
 1st dose, n (%) 1 (0.23)
 2nd dose, n (%) 8 (1.81)

Type of vaccine received, rates of adverse effects and disease flare